‘Building relationships for a better healthcare environment’

On the 24th of August 2001, a group of business and licensing executives united in Basel and founded the Swiss Pharma Licensing Group.  The first Board defined objectives, recruited members and set up the foundation for today’s association.

Read More…

Disruption or Evolution? Contemporary Trends in Pharma Business Development

The EPLC, together with this years’ hosts the PLCF, are pleased to welcome you to the romantic city of Paris for the XV IPLS from 18th – 20th September 2019. The IPLS event is a great opportunity for the healthcare deal-making community to come together to learn, discuss, network and partner.

Without question we live in interesting times, the 15th IPLS has been
designed to explore some of the more disruptive influences and opportunities in the life science industry today.

Early Booking Rate available until 26th April 2019!

Two days of informative presentations from industry leading speakers, peer to peer networking, one-to-one meeting opportunities and continuous personal development, all in the world’s most popular and dynamic city, Paris.

Conference Programme Includes:

Contemporary Trends in Pharma Business Development
Artificial Intelligence
Medical Cannabis
Evolution of Business Development Teams

Ageing, a New Field of Investigation & Investment
The Continuum of Ageing & Age-Related Diseases
Ageing Opportunities in Pharmaceuticals
New Therapeutic Advances

And much more, including 7 hours of dedicated one-to-one partnering
Full Programme & Event Website
 

REGISTER ONLINE NOW 
XV International Pharma Licensing Symposium
Pullman Hotel Paris Centre – Bercy
Paris, France
Wednesday 18th to Friday 20th September 2019


Who Should Attend? Business Development Professionals, Managing
Directors, General Managers, Business Owners, Investors, Advisors,
Financial, Marketing& Regulatory Executives

REGISTER ONLINE NOW

Swiss Healthcare Licensing Group 2018 Winter Conference – another fantastic success!

Basel, 16th February 2018 – The Swiss HLG, a non-profit association of Business Development and Licensing professionals, held its 27th Conference titled “ Reset Partnering – Step out of the Box!” With partnering deals increasing in complexity, the evolution from pharmaceuticals to solutions and the consumerization of healthcare, Business Development, and Licensing professionals need to ask themselves if the tools and approaches used are still fit for purpose in the healthcare world of 2018.

Over three days, more than 100 delegates from Switzerland, Europe, the US and Asia gathered in the Swiss Alps to explore and exchange on the future of partnering and to take a step out of the Box.

Conference Director, Chris Isler with the active support of the entire Swiss HLG Board, convened a global panel of leading experts from the healthcare and consumer industry addressing three main questions:

  • How can we find the right deal for a specific question?
  • What is required to partner beyond the molecule?
  • Are there any new approaches we can learn from the consumer industry?

Before the start of the conference, Anthony A. Hörning, CEO of Strategic Transactions Advisor and former head of Alliance Management at Novartis led a dynamic and interactive workshop helping participants to understand “What happens after marriage – managing complex alliances”.

As an introduction, Jean-Paul Clozel, CEO of Idorsia and former CEO of Actelion, brilliantly set the stage with his thought-provoking keynote speech on his company has been acquired by Johnson & Johnson, despite not willing himself to sell it. He brought the audience to think on how the relationship and trust dimension were important to make such a transaction a success.

Francesco De Rubertis, CEO of the Medicxi Venture Fund expanded on Clozel’s thoughts with the view from the VC’s perspective and explained how entrepreneurialism and venture capital could go hand in hand. He shared his opinion as VC vs JP Clozel vision as an entrepreneur.

One of the Swiss HLG objectives is not just professional but also personal development, and hence Design Thinking Master, Rana Lonnen, Head Search and Evaluation Strategic Venture Capital at Novartis Pharma opened the day on Monday exploring how design thinking approaches can be leveraged in a partnering setting.

Six captivating presentations illustrated then what, along with the partnering process, is required to find the right deal. Alan Selby, Executive Director at Torreya Partners, shared his thoughts on when to use a broker or not. Emma Barton, Director Alliance, and Integration Management at AstraZeneca explained how Outlicensing can preserve the value of a molecule. Shigeo Taniuchi, Head of EMEA, Senior Corporate officer at Santen Pharmaceutical and Viren Mahurkar, formerly at Alcon took a look at the cultural dimension of partnerships and what to bear in mind when working with partners in Japan or China.

Tanja Dowe, CEO of the Debiopharm Innovation Fund focused on how to find the right deal with a VC fund and last but not least Vikalp Mohan, Vice President Sales and Marketing at Celonic took a look at how to partner with a Contract Development and Manufacturing Organization.

After a full day of presentations, the delegates enjoyed a short walk and typical Swiss Fondue Dinner in a barn and used the opportunity to expand their personal and professional networks.

The last day of the conference focused on how to partner beyond the molecules, starting with a case study looking at how to make more out of data by Dr. Alexandra V. Eberhard, Managing Director Europe, and Executive VP Sciences at Signals Analytics. Michael Meissner, Chief Technology Officer, at Sanofi took a look at how technology is becoming increasingly important for pharma and asked the question if pharma in this picture is the boiling frog. Ravi Sodha, Senior Director, Business Development at Actelion closed this block in sharing his perspectives on what makes deals for rare diseases different.

The closing keynote, delivered by Jon Otterstatter, CEO of the Preventice Solutions Group took the audience along the journey of building a highly successful medical technology start-up from scratch to a 500+ employee organization with prominent investors such as Merck Inc or Boston Scientific.

The Swiss HLG Board thanks the presenters and the participants for the lively discussion and interactions. Please find below some images from the conference. (Please click on the image to view it in its entirety and or a slide show.)

 

 

Take a look at some impressions from our Winter Conference 2018.

Informative, exciting and a great opportunity to meet and exchange ideas with other Business Development Professionals.

https://www.flickr.com/photos/organizersgmbh/sets/72157691112123181/

 

We are excited to welcome you to our Winter Conference 2018!

We are thrilled to announce that we have more than 100 Business Development professionals attending our Winter Conference this year.

The next few days are the perfect opportunity to meet and build personal relationships with leading executives not only the from the healthcare industry, but our growing network from MedTech, Generics, Biosimilars, Investment & Finances, Biotech & Startup, Health Food Industry, Cosmetics and Legal & IP industries.

We look forward to the informative discussions about this year’s topic ” Reset Partnering- Step out of the Box!”

Join us, become a member !

Join Swiss HLG
as a member

Newsletter

Keep up to date with the latest information by signing up to our newsletter

Why it's worth joining us !

Learn more about Swiss HLG
and our initiatives